Abstract:Objective: To investigate the mechanism of isoliquiritigenin in the treatment of atopic dermatitis in mice through Janus kinase-signal transducer and activator of transcription(JAK-STAT) pathway. Methods: Sixty SPF male C57BL/6 mice were randomly divided into negative control group, model group, isoliquiritigenin low dose group (50 mg/kg), isoliquiritigenin high dose group (100 mg/kg) and positive control group (prednisolone, 10 mg/kg), with 12 mice in each group. In addition to the negative control group, 2,4-dinitrochlorobenzene (DNCB) was smeared on the back depilated area and ears of mice in other groups to prepare atopic dermatitis (AD) model. On the first day after successful modeling, mice in isoliquiritigenin low dose group, isoliquiritigenin high dose group and positive control group were given corresponding drugs by gavage, while mice in negative control group and model group were given the same amount of distilled water once a day. After 14 consecutive days, the mice were evaluated for scratching behavior and dermatitis score, and serum interleukin-4(IL-4), tumor necrosis factor-α(TNF-α) and immunoglobulin E(IgE) levels, the levels of JAK1, JAK3, STAT3 and STAT6 protein in the skin tissue were detected. Results: The skin of mice in negative control group was normal; the skin of mice in the model group showed varying degrees of erythema, dryness, scratches, epidermal erosion and shedding, and scabs; the symptoms of the isoliquiritigenin low and high dose groups were significantly alleviated, and the isoliquiritigenin high dose group had obvious curative effect; the positive control group has better efficacy than that in the isoliquiritin high dose group. Compared with the negative control group, the number of scratches, dermatitis score, IL-4, TNF-α, IgE, JAK1, JAK3, STAT3 and STAT6 protein in the other groups were increased (P<0.05). Compared with the model group, the number of scratches, dermatitis score, IL-4, TNF-α, IgE, JAK1, JAK3, STAT3 and STAT6 protein in the isoliquiritin low dose group, isoliquiritin high dose group and the positive control group decreased, and the effect in the isoliquiritin dose groups was dose-dependent, but the effect was not as good as the positive control group (P<0.05). Conclusion: Isoliquiritin has therapeutic effect on the skin lesions of AD model mice, and its mechanism may be related to the inhibition of JAK-STAT pathway.
李媛媛, 潘新锋, 池丽俏. 异甘草素通过JAK/STAT途径治疗小鼠特应性皮炎的机制研究[J]. 河北医学, 2021, 27(5): 710-715.
LI Yuanyuan, PAN Xinfeng, CHI Liqiao. Mechanism of Isoliquiritigenin in the Treatment of Atopic Dermatitis in Mice Through JAK-STAT Pathway. HeBei Med, 2021, 27(5): 710-715.